CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?

Cosso, Federica, Roviello, Giandomenico, Nesi, Gabriella, Shabani, Sonia, Spatafora, Pietro, Villari, Donata, Catalano, Martina·2023·International Journal of Molecular Sciences
DOI 10.3390/ijms24044243PMC PMC9959913
Open this paper in CoChat — free account

Abstract

Renal cell carcinoma (RCC) is the third most common genitourinary cancer accounting for approximately 180,000 deaths worldwide in 2020. Although over two-thirds of patients initially present localized disease, up to 50% of them may progress to metastatic disease. Adjuvant therapy aims to reduce the recurrence risk and improve outcomes in several types of cancers but is currently an unmet need in RCC. The results achieved with tyrosine kinase inhibitors in metastatic RCC led to the evaluation of these target therapies in an early setting with conflicting results for disease-free survival and no overall survival (OS) benefit. Likewise, the results of immune checkpoint inhibitors (ICIs) in an adjuvant setting are conflicting. Available data did not show an improvement in OS with ICIs in the early phase, although a positive trend for pembrolizumab has been recorded, receiving the Food and Drug Administration’s approval in this setting. However, the disappointing results of several ICIs and the heterogeneous pattern of RCC warrant biomarker identification and subgroup analyses to evaluate which patients could benefit from adjuvant therapy. In this review, we will discuss the rationale for adjuvant treatment in RCC, summarizing the results of the most important adjuvant therapy trials and current applications, to outline possible future directions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24044243

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Molecular and immunotherapy targets evaluated in adjuvant RCC. ICIs of PD-1 disrupt its interaction with PD-L1, leading to enhanced T-cell proliferation and activation. Antibodies targeting PD-L1 prevent its interaction with PD1 on CD8 T cells, allowing their activation. Anti-CTLA-4 antibodies allow CD28 to bind to its receptor, B7, and activate naïve CD4 T cells. Antiangiogenetic targets include TKIs on VEGFR. mTOR inhibitors prevent tumor growth. TAM, tumor-associated macrophage; RCC, renal cell carcinoma; ICIs, immune checkpoint inhibitors; PD-1/L-1, programmed cell death 1/ligand-1; CTLA4, cytotoxic T-lymphocyte antigen 4; TKIs, tyrosine kinase inhibitors; VEGFR, vascular endothelial growth factor receptor, mTOR, mammalian target of rapamycin; TAM, tumor-associated macrophages. Created in BioRender.com.
Figure 1 Molecular and immunotherapy targets evaluated in adjuvant RCC. ICIs of PD-1 disrupt its interaction with PD-L1, leading to enhanced T-cell proliferation and activation. Antibodies targeting PD-L1 prevent its interaction with PD1 on CD8 T cells, allowing their activation. Anti-CTLA-4 antibodies allow CD28 to bind to its receptor, B7, and activate naïve CD4 T cells. Antiangiogenetic targets include TKIs on VEGFR. mTOR inhibitors prevent tumor growth. TAM, tumor-associated macrophage; RCC, renal cell carcinoma; ICIs, immune checkpoint inhibitors; PD-1/L-1, programmed cell death 1/ligand-1; CTLA4, cytotoxic T-lymphocyte antigen 4; TKIs, tyrosine kinase inhibitors; VEGFR, vascular endothelial growth factor receptor, mTOR, mammalian target of rapamycin; TAM, tumor-associated macrophages. Created in BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 42

  1. Makino, T., Kadomoto, S., Izumi, K., and Mizokami, A. (2022). Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 14. · DOI
  2. Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 · DOI · Paper page
  3. Padala, 2020, Epidemiology of Renal Cell Carcinoma, World J. Oncol., 11, 79, 10.14740/wjon1279 · DOI
  4. Chowdhury, 2020, Kidney Cancer: An Overview of Current Therapeutic Approaches, Urol. Clin. North Am., 47, 419, 10.1016/j.ucl.2020.07.009 · DOI
  5. Eisen, 2020, Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results from the SORCE Randomized Phase III Intergroup Trial, J. Clin. Oncol., 38, 4064, 10.1200/JCO.20.01800 · DOI
  6. Kwon, 2018, Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial, Ann. Oncol., 29, 2371, 10.1093/annonc/mdy454 · DOI
  7. Haas, 2016, Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial, Lancet, 387, 2008, 10.1016/S0140-6736(16)00559-6 · DOI
  8. Motzer, 2017, Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma, J. Clin. Oncol., 35, 3916, 10.1200/JCO.2017.73.5324 · DOI
  9. Ravaud, 2016, Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy, New Engl. J. Med., 375, 2246, 10.1056/NEJMoa1611406 · DOI
  10. Ryan, 2022, EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249), J. Clin. Oncol., 40, LBA4500, 10.1200/JCO.2022.40.17_suppl.LBA4500 · DOI
  11. Thompson, 2015, Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach, J. Clin. Oncol., 33, 4151, 10.1200/JCO.2015.61.8009 · DOI
  12. Kim, 2011, Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell Carcinoma, Urology, 78, 1101, 10.1016/j.urology.2011.05.012 · DOI
  13. Sciarra, 2011, The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?, Crit. Rev. Oncol., 81, 151, 10.1016/j.critrevonc.2011.02.003 · DOI
  14. Gul, 2019, Adjuvant therapy in renal cell carcinoma, Cancer, 125, 2935, 10.1002/cncr.32144 · DOI
  15. Martini, 2021, Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma, World J. Urol., 39, 1369, 10.1007/s00345-020-03550-z · DOI
  16. Breda, 2007, Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection, Expert Rev. Anticancer. Ther., 7, 847, 10.1586/14737140.7.6.847 · DOI
  17. Speed, 2017, Recurrence in Localized Renal Cell Carcinoma: A Systematic Review of Contemporary Data, Curr. Urol. Rep., 18, 15, 10.1007/s11934-017-0661-3 · DOI
  18. Fuhrman, 1982, Prognostic significance of morphologic parameters in renal cell carcinoma, Am. J. Surg. Pathol., 6, 655, 10.1097/00000478-198210000-00007 · DOI
  19. Leibovich, 2003, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma, Cancer, 97, 1663, 10.1002/cncr.11234 · DOI
  20. Frank, 2002, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score, J. Urol., 168, 2395, 10.1016/S0022-5347(05)64153-5 · DOI
  21. Zisman, 2001, Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System, J. Clin. Oncol., 19, 1649, 10.1200/JCO.2001.19.6.1649 · DOI
  22. Harshman, 2017, Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis, Cancer, 124, 925, 10.1002/cncr.31154 · DOI
  23. Haas, 2021, Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy, J. Clin. Oncol., 39, 4581, 10.1200/JCO.2021.39.15_suppl.4581 · DOI
  24. Tuthill, 2020, Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date, OncoTargets Ther., 13, 12301, 10.2147/OTT.S174149 · DOI
  25. Sawhney, 2021, Adjuvant therapy for renal cell carcinoma, J. Cancer Metastasis Treat., 7, 48
  26. Motzer, 2021, Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial, Eur. Urol., 79, 334, 10.1016/j.eururo.2020.12.029 · DOI
  27. Massari, 2019, Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials, Clin. Genitourin. Cancer, 17, e339, 10.1016/j.clgc.2018.12.011 · DOI
  28. Marconi, 2021, Prevalence, Disease-free, and Overall Survival of Contemporary Patients with Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials, Clin. Genitourin. Cancer, 19, e92, 10.1016/j.clgc.2020.12.005 · DOI
  29. Rotte, 2018, Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy, Ann. Oncol., 29, 71, 10.1093/annonc/mdx686 · DOI
  30. Powles, 2022, Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 23, 1133, 10.1016/S1470-2045(22)00487-9 · DOI
  31. Renner, 2022, Adjuvant therapy for renal cell carcinoma, finally a new standard?, Front. Oncol., 12, 926661, 10.3389/fonc.2022.926661 · DOI
  32. Pal, 2022, Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial, Lancet, 400, 1103, 10.1016/S0140-6736(22)01658-0 · DOI
  33. Bedke, 2023, The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma, Eur. Urol., 83, 10, 10.1016/j.eururo.2022.10.010 · DOI
  34. Motzer, 2022, Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial, Ann. Oncol., 33, S808, 10.1016/j.annonc.2022.08.069 · DOI
  35. Allaf, 2021, PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143), J. Clin. Oncol., 39, 15, 10.1200/JCO.2021.39.15_suppl.TPS4596 · DOI
  36. Choueiri, 2022, LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC), J. Clin. Oncol., 40, TPS4602, 10.1200/JCO.2022.40.16_suppl.TPS4602 · DOI
  37. Berg, S.A., and McGregor, B.A. (2022). The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. Cancers, 14. · DOI
  38. Blick, 2017, Improving outcomes in high-risk, nonmetastatic renal cancer: New data and ongoing trials, Nat. Rev. Urol., 14, 753, 10.1038/nrurol.2017.123 · DOI
  39. Bex, 2022, LBA66 IMmotion010: Efficacy and Safety from the Phase III Study of Atezolizumab vs Placebo as Adjuvant Therapy in Patients with RCC at Increased Risk of Recurrence After Resection, Ann. Oncol., 33, S1431, 10.1016/j.annonc.2022.08.071 · DOI
  40. Weber, 2018, Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall’s τ, Stat. Med., 38, 703, 10.1002/sim.8001 · DOI
  41. Klatte, 2009, Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy, Cancer Epidemiol. Biomark. Prev., 18, 894, 10.1158/1055-9965.EPI-08-0786 · DOI
  42. Thompson, 2004, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proc. Natl. Acad. Sci. USA, 101, 17174, 10.1073/pnas.0406351101 · DOI · Paper page

Cited by

Sorted by citations

See all 18

Metadata

Authors
Cosso, F., Roviello, G., Nesi, G., Shabani, S., Spatafora, P., Villari, D., & Catalano, M.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-02-20
Volume
24
Issue
4
Pages
4243
ISSN
1422-0067
DOI
10.3390/ijms24044243
PMC
PMC9959913
Cited by
18
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? https://app.cochat.ai/papers/10.3390/ijms24044243
The paper
Cosso, F., Roviello, G., Nesi, G., Shabani, S., Spatafora, P., Villari, D., & Catalano, M. (2023). Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044243